Short answer
PTEN is a tumor-suppressor gene. A germline pathogenic or likely pathogenic PTEN variant can support a diagnosis in the PTEN hamartoma tumor syndrome spectrum, which includes Cowden syndrome and related conditions. Interpretation should separate inherited PTEN results from tumor-only findings, and should consider personal features such as macrocephaly, hamartomas, thyroid findings, colon polyps, skin or oral findings, neurodevelopmental history, and family cancer patterns. A PTEN VUS is uncertain and should not be handled like a confirmed harmful variant.
How to read the result
| Report wording | Practical meaning | What to ask next |
|---|---|---|
| Pathogenic or likely pathogenic germline PTEN variant | The lab found an inherited PTEN change with enough evidence to guide syndrome-level risk counseling. | Which PTEN hamartoma tumor syndrome features and cancer-surveillance conversations apply to this exact result? |
| PTEN variant of uncertain significance | The lab found a PTEN change, but its health meaning is not established. | Should care be based on clinical features and family history while the variant remains uncertain? |
| Negative PTEN result | No reportable PTEN variant was found in the test performed. | Was the test targeted to a known family variant, and did it include deletion or duplication analysis if clinically relevant? |
| Tumor-only PTEN finding | The PTEN change may be present only in cancer tissue rather than inherited DNA. | Is separate germline testing needed before relatives are told they may be at inherited risk? |
| Family variant testing | Relatives may be offered targeted testing when a confirmed familial pathogenic PTEN variant is known. | Does the report name the exact variant relatives should be tested for? |
Cancer-risk context to clarify
- PTEN hamartoma tumor syndrome can involve benign growths and increased risk for several cancers, including breast, thyroid, kidney, endometrial, colorectal, and melanoma according to NCI's definition.
- PTEN results are not interpreted from the gene name alone. The same report should be read with the person's clinical features, family history, age, and specimen type.
- Tumor-only PTEN alterations are common in some cancers and do not automatically mean a person has inherited PTEN hamartoma tumor syndrome.
- A negative result is most reassuring when a known familial PTEN variant was specifically tested. Without a known family variant, it may not rule out a hereditary explanation for symptoms or cancers.
- Children can be part of PTEN evaluation in some families, so genetic counseling should address the timing and purpose of testing for relatives.
Questions to bring to counseling
- Was PTEN tested from blood, saliva, cheek cells, tumor tissue, or paired tumor-normal testing?
- What is the exact PTEN variant notation and classification?
- Does this result fit Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, or the broader PTEN hamartoma tumor syndrome spectrum?
- Which cancer-risk and surveillance conversations are supported for my age, sex, personal history, and family history?
- Does the test method detect large deletions or duplications, or only sequence-level variants?
- Which relatives should consider targeted testing for a known family variant?
- How will I be notified if a PTEN VUS is reclassified?
When family history changes the next step
Follow-up matters more when the family history suggests a broader PTEN-related pattern than the report alone, when the result is uncertain, or when relatives may need targeted testing. Genetics counseling helps decide whether the next step is clinical syndrome review, tumor testing, or family testing.
When follow-up matters more
Follow-up matters more when the variant class is unclear, family history is strong, the result is a VUS, or the cancer history does not match the current screening plan. That is the point to confirm whether genetics counseling, tumor testing, or family testing changes the next step.
How genetic testing is done
Genetic testing is usually done with blood or saliva, and the lab workflow depends on whether the question is a targeted variant, a panel, or confirmation after a clinical finding. Genetics counseling can help clarify whether the next step is a new test, family testing, or a different clinical workup.
FAQ
Does a PTEN pathogenic variant mean cancer is certain?
No. It raises inherited risk, but it does not make cancer certain.
Does a PTEN VUS change care?
No. A PTEN variant of uncertain significance should not be treated like a confirmed pathogenic result.
Does a negative PTEN result rule out hereditary risk?
Not always. A negative result can still miss some hereditary explanations if the family pattern fits PTEN-related disease or another syndrome.
Does tumor-only PTEN prove inherited syndrome?
No. A tumor-only PTEN alteration can help explain a cancer, but it does not by itself prove germline PTEN hamartoma tumor syndrome.
Should relatives be tested?
If a familial pathogenic PTEN variant is known, relatives may be offered targeted testing.
What should counseling clarify first?
The exact variant, specimen type, Cowden/overlap features, and the personal and family tumor pattern.
Related guides: hereditary cancer genetic testing, tumor genomic vs inherited genetic testing, BRCA VUS result interpretation, Lynch syndrome genetic testing, and when to use a genetic counselor.